Cancer in Pacific Populations in New Zealand and ctDNA technology for early cancer detection

Abstract

Abstract The burden of cancer amongst Pacific Peoples living in New Zealand and in the Pacific Region remains a public health concern. The utilization of a simple blood sample to enable the detection and monitoring of cancer growth is an attractive alternative to obtaining invasive biopsy samples from solid cancers in people. This can be achieved through the use of circulating tumour DNA (ctDNA) detection which refers to small fragments of tumour DNA found in the blood circulation that can be isolated and analysed to allow monitoring of tumour size and progression. This method of cancer monitoring and the potential for early cancer detection, will enhance the precision of cancer diagnostics and surveillance that will likely lead to improved cancer health outcomes over time. This work sought to investigate the potential utilization of ctDNA to support and improve the diagnosis, care and health outcomes of Pacific cancer patients in the New Zealand. A high degree of support and interest was expressed by health professionals, researchers, senior academics and lay persons engaged with for the development of ctDNA as a potential diagnostic tool for early cancer detection, particularly with regards to achieving reductions in adverse cancer statistics and addressing inequalities. As in the Pacific Region, one of the key features of interest was the potential for frail or remotely located patients to be monitored for their cancer without their need to travel or be transported to the Hospital setting which can create a significant source of stress for some. The applicability of ctDNA as an early cancer detection method was explored in depth and received with approval within the research, academic and clinical health care settings.